Everhart Financial Group Inc. Sells 76,379 Shares of SELLAS Life Sciences Group, Inc. $SLS

Everhart Financial Group Inc. decreased its holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 21.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 288,018 shares of the company’s stock after selling 76,379 shares during the quarter. Everhart Financial Group Inc. owned about 0.15% of SELLAS Life Sciences Group worth $4,251,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock worth $2,714,000 after purchasing an additional 540,748 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after purchasing an additional 1,709 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of SELLAS Life Sciences Group by 20.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 45,691 shares of the company’s stock worth $193,000 after purchasing an additional 7,673 shares during the period. Quantinno Capital Management LP bought a new stake in shares of SELLAS Life Sciences Group during the 1st quarter valued at about $315,000. Finally, Independent Financial Group LLC bought a new stake in shares of SELLAS Life Sciences Group during the 1st quarter valued at about $98,000. Institutional investors own 17.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Trading Up 2.6%

Shares of SELLAS Life Sciences Group stock opened at $12.01 on Friday. SELLAS Life Sciences Group, Inc. has a 12 month low of $1.39 and a 12 month high of $15.88. The firm has a market capitalization of $2.36 billion, a P/E ratio of -52.22 and a beta of 2.48. The business has a fifty day simple moving average of $10.92 and a two-hundred day simple moving average of $7.13.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.